RNF182: A Potential Drug Target for NFKB-Induced Cellular Processes
RNF182: A Potential Drug Target for NFKB-Induced Cellular Processes
The nuclear factor kappa B (NFKB) signaling pathway is a critical regulator of immune and inflammatory responses. The NFKB pathway is activated in response to various stimuli, including cytokines and tissue damage-associated molecular targets (TAMMs). One of the key transcription factors activated by the NFKB pathway is the RNA factor 182 (RNF182), which is a 24-kDa protein that plays a critical role in the regulation of inflammation and immune responses.
RNF182 is a highly conserved gene that is expressed in various tissues and cell types, including immune cells, neurons, and epithelial cells. It is a key transcription factor that is involved in the regulation of NFKB signaling pathway, which is a critical pathway for the regulation of immune and inflammatory responses.
The NFKB pathway is a complex signaling pathway that is involved in the regulation of various cellular processes, including cell growth, apoptosis, angiogenesis, and inflammation. The NFKB pathway is activated in response to various stimuli, including cytokines and tissue damage-associated molecular targets (TAMMs).
RNF182 is a key transcription factor that is involved in the regulation of the NFKB pathway. It is a 24-kDa protein that is composed of two distinct domains: a N-terminal domain and a C-terminal domain. The N-terminal domain is responsible for the regulation of DNA binding, while the C-terminal domain is responsible for the regulation of protein interactions.
RNF182 is a member of the NF-kappa-B-activating transcription factor (NFAT) family, which is a subfamily of the NF-kappa-B signaling pathway. NFATs are a group of transcription factors that are involved in the regulation of NFKB signaling pathway. They are characterized by the presence of a nuclear export signal (NES), which is a critical factor for the translation of the protein into the nucleus.
RNF182 is involved in the regulation of various cellular processes, including inflammation, cell growth, apoptosis, and angiogenesis. It is a key factor in the regulation of inflammation, as it is involved in the regulation of the production and activation of immune cells.
RNF182 is also involved in the regulation of cell growth and apoptosis. It is a positive regulator of cell growth, as it can increase the expression of genes involved in cell growth and survival. It is also involved in the regulation of apoptosis, as it can induce the expression of genes involved in apoptosis.
RNF182 is also involved in the regulation of angiogenesis, as it is involved in the regulation of the formation of blood vessels. It is a positive regulator of angiogenesis, as it can increase the expression of genes involved in angiogenesis.
Drug targeting
Drug targeting is a strategy that is used to inhibit the activity of a specific protein or to activate its activity. It is a technique that is used to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.
RNF182 is a potential drug target, as it is involved in the regulation of various cellular processes and is a key transcription factor that is involved in the NFKB pathway. It is a good candidate for drug targeting due to its small size, its high degree of conservation, and its involvement in the regulation of various cellular processes.
Conclusion
RNF182 is a 24-kDa protein that is involved in the regulation of the NFKB pathway. It is a key transcription factor that is involved in the regulation of various cellular processes, including inflammation, cell growth, apoptosis, and angiogenesis. It is a potential drug target due to its small size, its high degree of conservation, and its involvement in the regulation of various cellular processes. Further research is needed to fully understand the role of RF
Protein Name: Ring Finger Protein 182
Functions: E3 ubiquitin-protein ligase that mediates the ubiquitination of ATP6V0C and targets it to degradation via the ubiquitin-proteasome pathway (PubMed:18298843). Also plays a role in the inhibition of TLR-triggered innate immune response by mediating 'Lys'-48-linked ubiquitination and subsequent degradation of NF-kappa-B component RELA (PubMed:31432514)
The "RNF182 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF182 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11 | RNU12 | RNU2-1 | RNU2-17P | RNU2-2P | RNU2-4P | RNU2-54P | RNU2-5P | RNU2-6P | RNU4-1 | RNU4-14P | RNU4-2 | RNU4-30P | RNU4-33P | RNU4-38P | RNU4-39P | RNU4-46P
